Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNTBNYSE:NHWKNASDAQ:STTKNASDAQ:VRCA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTBConnect Biopharma$0.82-0.2%$0.76$0.51▼$2.08$45.39M-0.2256,416 shs39,619 shsNHWKNightHawk Biosciences$0.39$0.26▼$1.16$10.78M0.1997,242 shs173,100 shsSTTKShattuck Labs$1.08+9.2%$1.06$0.69▼$11.76$51.73M1.76379,579 shs180,516 shsVRCAVerrica Pharmaceuticals$0.47+1.3%$0.54$0.38▼$11.41$43.48M1.68582,932 shs128,955 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTBConnect Biopharma+1.43%+20.82%+49.38%-15.30%-40.89%NHWKNightHawk Biosciences0.00%0.00%0.00%0.00%0.00%STTKShattuck Labs+19.03%+16.18%+4.09%-20.88%-90.56%VRCAVerrica Pharmaceuticals+0.98%+1.20%+4.98%-35.28%-93.34%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCNTBConnect Biopharma2.5953 of 5 stars3.53.00.00.01.82.50.6NHWKNightHawk BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ASTTKShattuck Labs2.7204 of 5 stars3.42.00.00.03.31.71.3VRCAVerrica Pharmaceuticals3.9375 of 5 stars3.12.00.04.71.63.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNTBConnect Biopharma 3.00Buy$8.00875.61% UpsideNHWKNightHawk Biosciences 0.00N/AN/AN/ASTTKShattuck Labs 2.71Moderate Buy$7.50594.44% UpsideVRCAVerrica Pharmaceuticals 2.20Hold$9.501,919.99% UpsideCurrent Analyst Ratings BreakdownLatest NHWK, STTK, CNTB, and VRCA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/9/2025VRCAVerrica PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold4/8/2025VRCAVerrica PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/31/2025CNTBConnect BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.003/27/2025STTKShattuck LabsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold3/27/2025STTKShattuck LabsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/17/2025STTKShattuck LabsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/17/2025STTKShattuck LabsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$4.003/12/2025VRCAVerrica PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNTBConnect Biopharma$24.12M1.88N/AN/A$1.83 per share0.45NHWKNightHawk Biosciences$6.38M0.00N/AN/A$2.82 per share0.00STTKShattuck Labs$5.72M9.04N/AN/A$3.41 per share0.32VRCAVerrica Pharmaceuticals$7.57M5.75N/AN/A$0.47 per share1.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNTBConnect Biopharma-$59.50MN/A0.00N/AN/AN/AN/AN/AN/ANHWKNightHawk Biosciences-$43.44M-$1.99N/AN/AN/A-2,333.27%-91.62%-56.48%N/ASTTKShattuck Labs-$87.30M-$1.49N/AN/AN/A-1,156.46%-61.92%-54.49%5/1/2025 (Estimated)VRCAVerrica Pharmaceuticals-$67M-$1.54N/AN/AN/A-625.06%-591.84%-141.63%5/12/2025 (Estimated)Latest NHWK, STTK, CNTB, and VRCA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025VRCAVerrica Pharmaceuticals-$0.10N/AN/AN/A$2.53 millionN/A5/1/2025Q1 2025STTKShattuck Labs-$0.29-$0.27+$0.02-$0.27N/AN/A3/27/2025Q4 2024STTKShattuck Labs-$0.38-$0.37+$0.01-$0.37$1.00 millionN/A3/11/2025Q4 2024VRCAVerrica Pharmaceuticals-$0.25-$0.24+$0.01-$0.24$1.30 million$0.34 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCNTBConnect BiopharmaN/AN/AN/AN/AN/ANHWKNightHawk BiosciencesN/AN/AN/AN/AN/ASTTKShattuck LabsN/AN/AN/AN/AN/AVRCAVerrica PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNTBConnect BiopharmaN/A12.04N/ANHWKNightHawk Biosciences0.270.990.99STTKShattuck LabsN/A7.967.96VRCAVerrica PharmaceuticalsN/A1.341.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNTBConnect Biopharma58.72%NHWKNightHawk Biosciences21.16%STTKShattuck Labs58.74%VRCAVerrica Pharmaceuticals42.45%Insider OwnershipCompanyInsider OwnershipCNTBConnect Biopharma22.60%NHWKNightHawk Biosciences15.90%STTKShattuck Labs10.50%VRCAVerrica Pharmaceuticals42.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNTBConnect Biopharma11055.35 million42.77 millionOptionableNHWKNightHawk Biosciences7726.08 million21.94 millionOptionableSTTKShattuck Labs10047.90 million42.73 millionOptionableVRCAVerrica Pharmaceuticals4092.46 million26.18 millionOptionableNHWK, STTK, CNTB, and VRCA HeadlinesRecent News About These CompaniesVerrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New YorkApril 30 at 8:00 AM | globenewswire.comVerrica Pharmaceuticals (NASDAQ:VRCA) Earns Hold Rating from Needham & Company LLCApril 11, 2025 | marketbeat.comHC Wainwright Has Optimistic Outlook of VRCA FY2028 EarningsApril 11, 2025 | marketbeat.comHC Wainwright Reaffirms Neutral Rating for Verrica Pharmaceuticals (NASDAQ:VRCA)April 10, 2025 | marketbeat.comWhy Verrica Pharmaceuticals Inc.’s (VRCA) Stock Is Down 5.94%April 10, 2025 | aaii.comVerrica Pharmaceuticals Reports Strong First-Quarter Growth for YCANTHApril 9, 2025 | msn.comIn face of U.S. stock market selloff, shares of West Chester firm are on the riseApril 8, 2025 | bizjournals.comVerrica Pharmaceuticals experiences ‘strong demand-led growth’ for YCANTH in Q1April 8, 2025 | markets.businessinsider.comVerrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025April 7, 2025 | markets.businessinsider.comRBC Capital Sticks to Their Hold Rating for Verrica Pharmaceuticals (VRCA)April 5, 2025 | markets.businessinsider.comVerrica Pharmaceuticals Adds Dr. Gavin Corcoran to Board of DirectorsApril 4, 2025 | msn.comVerrica Pharmaceuticals Appoints Dr. Corcoran as DirectorApril 2, 2025 | tipranks.comVerrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of DirectorsApril 2, 2025 | globenewswire.comVerrica Pharmaceuticals to Present at Needham Healthcare ConferenceApril 2, 2025 | msn.comHere's Why Verrica Pharmaceuticals (VRCA) Is a Great 'Buy the Bottom' Stock NowApril 1, 2025 | zacks.comHarmony, Lungpacer, Verrica and Arbutus make C-suite hiresApril 1, 2025 | bizjournals.comVerrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare ConferenceMarch 31, 2025 | globenewswire.comVerrica Pharmaceuticals Appoints Dr. Noah Rosenberg as Chief Medical OfficerMarch 28, 2025 | msn.comVerrica Pharmaceuticals appoints Rosenberg as CMOMarch 26, 2025 | markets.businessinsider.comVerrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical OfficerMarch 26, 2025 | markets.businessinsider.comVerrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D.March 26, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNHWK, STTK, CNTB, and VRCA Company DescriptionsConnect Biopharma NASDAQ:CNTB$0.82 0.00 (-0.19%) Closing price 03:51 PM EasternExtended Trading$0.84 +0.02 (+2.44%) As of 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.NightHawk Biosciences NYSE:NHWKNightHawk Biosciences, Inc., an integrated biopharmaceutical company, develops, manufactures, and commercializes medical countermeasures that combat unmet and emerging biothreats. The company develops ANTHIM (obiltoxaximab), a monoclonal antibody antitoxin for the treatment of inhalational anthrax. The company was formerly known as Heat Biologics, Inc. and changed its name to NightHawk Biosciences, Inc. in May 2022. NightHawk Biosciences, Inc. was incorporated in 2008 and is based in Morrisville, North Carolina.Shattuck Labs NASDAQ:STTK$1.08 +0.09 (+9.20%) Closing price 04:00 PM EasternExtended Trading$1.04 -0.04 (-3.24%) As of 06:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.Verrica Pharmaceuticals NASDAQ:VRCA$0.47 +0.01 (+1.31%) Closing price 04:00 PM EasternExtended Trading$0.46 -0.01 (-1.76%) As of 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Crushes Earnings, What’s Next for MSFT Stock? McDonald’s Insiders Sell Shares! Investors Should Do the Opposite Qualcomm's Earnings: 2 Reasons to Buy, 1 to Stay Away Broadcom: Buy, Hold, Sell? AI & Acquistions Paint Strong Picture Hershey Hits the Sweet Spot for Defensive Investors A Bull Case for Adobe Stock Remains Today AMD Stock Signals Strong Buy Ahead of Earnings BigBear.ai: A Short-Squeeze Is Possible, a Sharp Drop Is Likely Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
